Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
PHILADELPHIA, Oct. 25, 2023 - Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California. Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented.
Oral & Poster Presentations:
- In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy
- Primary Author: Bindu Varghese, PhD
- Presentation Type/#: Oral – 1514
- Session Date/Time (PT): Friday, November 3, 2023, 11:30 am, Session 104: Late Breaking Abstract Session
- CAR-Macrophages with custom intronic shRNA exhibit enhanced efficacy against solid tumors
- Primary Author: Chris Sloas, PhD
- Presentation Type/#: Poster – 307
- Session Date/Time: Friday, November 3, 2023, 9:00 am – 7:00 pm
- Engineered Microenvironment Converters (EM-C): Macrophages expressing synthetic cytokine receptors reverse immunosuppressive signals in solid tumors
- Primary Author: Chris Sloas, PhD
- Presentation Type/#: Poster – 389
- Session Date/Time: Friday, November 3, 2023, 9:00 am – 7:00 pm
- A Phase 1, First in Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors
- Primary Author: Kim Reiss, MD
- Presentation Type/#: Poster – 635
- Session Date/Time: Friday, November 3, 2023, 9:00 am – 7:00 pm
Presentation and posters will be available in the Journal for ImmunoTherapy of Cancer (JITC) supplement once published on Tuesday, October 31, 2023, at 9:00 am ET.